A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UNCOVER-1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Dec 2016 Results of an integrated analysis of UNCOVER-1, UNCOVER-2, UNCOVER-3, UNCOVER-A, UNCOVER-J and two other phase 1 and phase 2 studies published in the Journal of the American Academy of Dermatology.
    • 27 Sep 2016 Combined results from three phase III trials (UNCOVER-1, 2 AND 3) published in the Journal of the American Academy of Dermatology.
    • 27 Sep 2016 According to an Eli Lilly media release, results from this trial will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV) 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top